StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

TScan Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -1655.4%. For fiscal 2025 it was -1256.8%, against -4527.7% the year before. The highest annual figure on record is -423.9% in fiscal 2023.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1256.8%+3270.8
FY2024Dec 31, 2024-4527.7%−4103.8
FY2023Dec 31, 2023-423.9%+65.4
FY2022Dec 31, 2022-489.3%−9.8
FY2021Dec 31, 2021-479.5%+1928.5
FY2020Dec 31, 2020-2408.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2888.6%−1687.3
Q1 FY2026Mar 31, 2026-2919.1%−1347.2
Q4 FY2025Dec 31, 2025-895.1%+4489.7
Q3 FY2025Sep 30, 2025-1422.1%+1427.0
Q2 FY2025Jun 30, 2025-1201.3%+4705.6
Q1 FY2025Mar 31, 2025-1571.9%+3753.5
Q4 FY2024Dec 31, 2024-5384.8%−5112.8
Q3 FY2024Sep 30, 2024-2849.1%−2257.5
Q2 FY2024Jun 30, 2024-5906.9%−5143.1
Q1 FY2024Mar 31, 2024-5325.4%−4993.8
Q4 FY2023Dec 31, 2023-272.0%+333.0
Q3 FY2023Sep 30, 2023-591.6%−108.6
Q2 FY2023Jun 30, 2023-763.8%−391.6
Q1 FY2023Mar 31, 2023-331.7%+203.1
Q4 FY2022Dec 31, 2022-604.9%−107.4
Q3 FY2022Sep 30, 2022-483.1%+173.6
Q2 FY2022Jun 30, 2022-372.2%+2.6
Q1 FY2022Mar 31, 2022-534.8%−144.5
Q4 FY2021Dec 31, 2021-497.5%+484.5
Q3 FY2021Sep 30, 2021-656.7%+1815.7
Q2 FY2021Jun 30, 2021-374.8%–
Q1 FY2021Mar 31, 2021-390.3%–
Q4 FY2020Dec 31, 2020-982.0%–
Q3 FY2020Sep 30, 2020-2472.4%–

More TScan Therapeutics figures

See a number that looks wrong?